Area of Expertise: Alternative donors; immunotherapy
Dr. Daniel Weisdorf is Professor of Medicine and Director of the Adult Blood and Marrow Transplant Program at the University of Minnesota. Dr. Weisdorf received his M.D. in 1975 from the Chicago Medical School and received Internal Medicine training at Michael Reese Hospital in Chicago. He was a Fellow at the University of Minnesota in Hematology and Medical Oncology and is Board certified in both disciplines.
Dr. Weisdorf’s clinical and research interests are in application of blood and marrow transplant therapies for hematologic malignancies as well as extensive study of the clinical complications of transplantation including opportunistic infections and graft versus host disease (GVHD). He serves as the Scientific Director of the National Marrow Donor Program and chairs the Acute Leukemia Committee of the International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry and is the University of Minnesota Principal Investigator on the NIH-sponsored Bone Marrow Transplantation Clinical Trials Network.
Selected Publications
McGlave PB, Xiao OS, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225.
van Burik JH and Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematology/Oncology Clinics of North America 1999;13(5): 1065-1089.
Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM, Burns LJ, Wagner JE, Eastlund T, Dusenbery K, Weisdorf DJ. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Bone Marrow Transplantation 2000; 26:723-728.
Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biology of Blood and Marrow Transplantation 2000; 6:280-288.
Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NKC, Wagner J, Enright H: Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplantation. Bone Marrow Transplantation 2000; 26:865-869.
Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB, Weisdorf DJ: Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplantation 2000; 26:1173-1177.
Weisdorf D, Dharan B, Horowitz M: Transplantation therapy for adults with acute lymphoblastic leukemia: Comparative analysis of autologous and unrelated donor bone marrow transplantation. In: Autologous Blood and Marrow Transplantation, Proceedings of the Tenth International Symposium, July 2000, Dallas, Texas, KA Dicke & A Keating (eds.): Charlottesville, VA, Carden Jennings Publishing Co., Ltd., 380-384, 2001.
Burns LJ, Weisdorf DJ, Defor TE, Repka TL, Ogle KM, Hummer C, Miller JS: Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with IL-2 plus G-CSF in patients with advanced breast cancer. Experimental Hematology 2000; 28:96-103.
Weisdorf D: Current controversies in bone marrow transplantation. Ann Intern Med 2000; 133:932.
Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, Weisdorf D, McGlave P: Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for CML: The U.S. National Marrow Donor Program Experience. Blood 2001; 98:2922-2929.
Arora M, Wagner JE, Davies SM, Blazar BR, DeFor T, Enright H, Miller WJ, Weisdorf DJ: Randomized clinical trial of thalidomide, cyclosporine and prednisone versus cyclosporine and prednisone as initial therapy of chronic graft versus host disease. Biology of Blood and Marrow Transplantation 2001; 7:265-273.
Barker JN, Weisdorf DJ, Wagner JE: Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001; 344:1870-1871.
Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, Kurtzberg J, Weisdorf DJ, Wagner JE: Low incidence of epstein-barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biology of Blood and Marrow Transplantation 2001; 7:395-399.
Weisdorf D, Anderson, JW, Glick, JH, & Oken, MM: Survival after relapse of low-grade non-Hodgkin’s lympohoma: Implications for marrow transplantation. Classic Papers and Current Comments 2001; 6: 496-502.
MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NKC, Wagner JE, Blazar BR: Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 2002; 8:40-46.
Toor AA, Slungaard A, Hedner U, Weisdorf DJ, Key NS: Post-transplant complications: Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2002; 29:403-408.
Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99:1971-1977.
Barker JN, Davies SM, DeFor TE, Burns LJ, McGlave PB, Miller JS, Weisdorf DJ. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. Br J Haematol 2002; 118:101-7.
van Burik JA, Weisdorf DJ. Is it time for a new look at granulocyte transfusions? Transfusion 2002; 42:1393-1395.
Anderson, D, Weisdorf, D: Blood vs. Marrow Allogeneic Stem Cell Transplantation. Chapter 8, 103-115. Allogeneic Stem Cell Transplantation: Clinical Research and Practice. Humana Press, Edited by: Mary J. Laughlin, M.D., & Hillard M. Lazarus, M.D., 2003.
Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, van Burik JA, Weisdorf DJ. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplantation 2002; 30:945-951.
Anderson D, Defor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D: A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic GVHD and infections. Biol Blood Marrow Transplant 2003; 9:52-59.
Dahl E, Burroughs J, DeFor T, Verfaillie C, Weisdorf D: Progenitor content of autologous grafts: Mobilized bone marrow versus mobilized blood. Bone Marrow Transplant 2003; 32:575-80.
Arora M, Burns LJ, Davies SM, Macmillan ML, DeFor TE, Miller WJ, Weisdorf DJ: Chronic grave-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9:38-45.
Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar RB, Burger SR, Panckaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS: IL-2 based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003; 32:177-86.
Dudek A, Mahaseth H, Defor T, Weisdorf DJ: Bronchiolitis obliterans in chronic graft versus host disease: Analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplantation 2003; 9:657-666.
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan N. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9:512-518.
MacMillan ML, Radloff GA, Kiffmeyer WR, DeFor TE, Weisdorf DJ, Davies SM. High producer IL-2 genotype increases risk for acute GVHD after unrelated donor bone marrow transplantation. Transplantation 2003; 76:1758-1762.
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan NA. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9:512-518.
Koreth R, Weinert C, Weisdorf D, Key N: Measurement of bleeding severity: A critical review. Transfusion. 2004; 44:605-17.
Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005; 11:129-35.
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005 Jan 4; [Epub ahead of print]
Barker JN, Weisdorf DJ, Defor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343-7.
Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215-22.
Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE, Weisdorf DJ. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005; 35: 1133-40.
Weisdorf DJ. Chronic graft-versus-host disease: where is promise for the future? Leukemia 2005; 19: 1532-5. (review).
Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-6.
Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005; 23: 7032-42.
Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107: 3804-7.
Arora M, Nagaraj S, Witte J, Defor TE, Macmillan M, Burns LJ, Weisdorf DJ. New classification of chronic GVHD: Added clarity from the consensus diagnoses. Bone Marrow Transplant. 2008; [Epub ahead of print]
Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2008; 14:1017-1021.
Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ.. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-992.
Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE, Weisdorf DJ. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14:538-545.
Marks DI, Perez WS, He W, Zhang MJ, Biship MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008; 112:426-434.
Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008; 14:282-289.
Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 41:635-642.
Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D. Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match. Biol Blood Marrow Transplant. 2008; 14: 1334-40.
Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2008 Oct 22; [Epub ahead of print].
Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. PMID: 19135940
Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009 Jan 12. [Epub ahead of print] PMID: 19139736
Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens. Bone Marrow Transplant. 2008 Dec 22; [Epub ahead of print] PMID: 19104492
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009 Feb;15(2):214-22. PMID: 19167681
Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with Plerixa for in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15:249-56.
Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (Allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Feb 9. [Epub ahead of print] PMID: 19204709
Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf EW. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Feb 17. [Epub ahead of print]
Bachanova V, Verneris MR, Defor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia (ALL) following reduced intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Jan 28. [Epub ahead of print] PMID: 19179301
Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with Plerixa for in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15:249-56. PMID: 19167685
Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (Allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Feb 9. [Epub ahead of print] PMID: 19204709
Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant. 2009; 15:30-8. PMID: 19135940
Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity. Blood. 2009 Mar 27. [Epub ahead of print] PMID: 19329778
Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 Mar 26.[Epub ahead of print] PMID: 19322205
Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, Devetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 Mar 6. [Epub ahead of print] PMID: 19270260
